Allos to conduct second interim analysis of Enrich trial, announce new data from phase 1/ 2 PDX trial

By Jennifer Lanning Drey

Eugene, Ore., Sept. 11 - Allos Therapeutics, Inc. will conduct a second interim analysis of the Enrich study of Efaproxyn (efaproxiral) in women with brain and breast cancer in the second half of fiscal 2006, Paul Berns, chief executive officer of Allos, said Monday at the Bear Stearns health care conference.

In addition, the company will present updated results later this year from its ongoing phase 1/ 2 clinical trial of PDX (pralatrexate) in patients with non-Hodgkin's lymphoma, Berns said.

Efaproxyn and PDX are Allos' two lead product candidates.

The company expects positive results from the Efaproxyn Enrich trial and has already begun pre-launch planning for the drug, Berns said.

"We think this [Enrich trial] is an extremely important step forward. We know so through our market research with radiation oncologist and clinical medical oncologists that there's significant enthusiasm building for the potential utility of Efaproxyn in this setting," Berns said.

The company completed enrollment in the Enrich trial in August. Survival is the primary endpoint for the study, while secondary endpoints include response rate in the brain at three months.

Final data from the trial is expected in mid-2007, Berns said.

Efaproxyn also is being studied in a phase 1 clinical trial as treatment for other primary tumors including those associated with non-small cell lung cancer and cervical cancer, he said.

Allos is a Westminster, Colo., biopharmaceutical company focused on cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.